ReviewBioactive materials2026
Advancements in dual-targeting nanoparticle strategies for enhanced atherosclerosis therapy: Overcoming limitations of single-targeting approaches.
Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.Journal of biomedical science · 2026Review
- Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- How Advanced is Nanomedicine to Treat Atherosclerosis? A Comprehensive Review of the Literature.International journal of nanomedicine · 2026Review
- Biomaterials Promote the Regression of Atherosclerotic Plaque by Regulating Cell Behavior.International journal of nanomedicine · 2026Review
- The Multifaceted Role of Platelets in Atherosclerosis and Ischemic Disease: Pathogenesis, Inflammation, and Therapeutic Opportunities.Life (Basel, Switzerland) · 2025Review
- The research progress of LACC1.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis treatment remains challenging, particularly in terms of developing effective targeted drug delivery strategies to enhance therapeutic efficacy. As research advances, considerable attention has been paid to identifying specific cell types and subcellular organelles-based on molecular mechanisms, damage progression, and drug action-to design next-generation nanoformulations with greater precision. Dual-targeting nanoparticles, which integrate numerous targeting modalities, offer a promising approach to precise drug delivery to pathological plaque sites. By enabling sequential and synchronous navigation of the targeting moieties, these strategies offer greater control over drug delivery than conventional methods. In this review, we discuss the pathological process of atherosclerosis and examine the progress made in its treatment using rationally designed nanoparticles over recent decades. We critically evaluate the limitations of single-targeting strategies and explore potential areas for improvement. Further, we provide a comprehensive overview of the classification and core principles of dual-targeting methods, thereby evaluating their efficiency. Finally, we discuss the design and application of strategies that integrate targeting ligands with stimulus-responsive moieties or nanobiomimetic techniques, thereby demonstrating their potential to address ligand-based dual-targeting nanotechnology limitations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.